Heron Therapeutics Inc (HRTX)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Heron Therapeutics Inc (HRTX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8012212
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月14日
◆ページ数:46
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Heron Therapeutics Inc (Heron), formerly A.P. Pharma, Inc., is a biotechnology company that uses its proprietary polymer-based drug delivery platform to develop novel, patient-focused therapeutic products for patients suffering from cancer and pain. Its proprietary Biochronomer technology is a polymer-based drug delivery platform, which improves the therapeutic profile of injectable pharmaceuticals. The company’s first commercial product Sustol is an extended-release injection indicated in combination with other antiemetics in adults for the prevention of moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. Heron’s developmental pipeline includes HTX-011 for post-operative pain management and Cinvanti (HTX-019) for chemotherapy-induced nausea and vomiting (CINV) prevention. Heron is headquartered in San Diego, California, the US.

Heron Therapeutics Inc (HRTX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Heron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Heron Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Heron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Heron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Heron Therapeutics Inc, Medical Devices Deals, 2011 to YTD 2017 10
Heron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Heron Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Equity Offering 12
Heron Therapeutics Prices Public Offering of Shares for USD150 Million 12
Heron Therapeutics Raises USD172.6 Million in Public Offering of Shares 14
Heron Therapeutics Raises USD137 Million in Public Offering of Shares 16
Heron Therapeutics Raises USD55.8 Million in Public Offering of Shares 18
Heron Therapeutics Raises USD7 Million in Private Placement of Warrants 20
A.P. Pharma Completes Public Offering Of Shares For US$60 Million 21
A.P. Pharma Completes Private Placement Of Common Stock For US$54 Million 23
A.P. Pharma Completes Private Placement Of Units For US$24 Million 24
Debt Offering 25
A.P. Pharma Completes Intial Closing Of Private Placement Of Convertible Notes For US$1.5 Million 25
Heron Therapeutics Inc – Key Competitors 26
Heron Therapeutics Inc – Key Employees 27
Heron Therapeutics Inc – Locations And Subsidiaries 28
Head Office 28
Other Locations & Subsidiaries 28
Recent Developments 29
Financial Announcements 29
Nov 06, 2017: Heron Therapeutics Reports Financial Results for the Three and Nine Months Ended September 30, 2017 and Recent Corporate Progress 29
Aug 09, 2017: Heron Therapeutics Reports Financial Results for the Three and Six Months Ended June 30, 2017 and Recent Corporate Progress 30
May 10, 2017: Heron Therapeutics Reports Financial Results for the Three Months Ended March 31, 2017 and Recent Corporate Progress 31
Feb 23, 2017: Heron Therapeutics Announces Fourth Quarter and Full Year 2016 Financial Results and Recent Corporate Progress 32
Nov 08, 2016: Heron Therapeutics Reports Financial Results for the Three and Nine Months Ended September 30, 2016 and Recent Corporate Progress 33
Aug 08, 2016: Heron Therapeutics Reports Second Quarter 2016 Financial Results and Recent Corporate Progress 34
May 05, 2016: Heron Therapeutics Announces First Quarter 2016 Financial Results and Recent Corporate Progress 35
Feb 19, 2016: Heron Therapeutics Announces Fourth Quarter and Full Year 2015 Financial Results and Recent Corporate Progress 36
Corporate Communications 37
Apr 24, 2017: Heron Therapeutics Appoints Robert E. Hoffman as Chief Financial Officer and Senior Vice President, Finance 37
Jun 22, 2016: Heron Therapeutics Announces Appointment of Christian Waage to Board of Directors 38
Clinical Trials 39
Jan 04, 2017: Heron Therapeutics Announces Positive Topline Results From Phase 2 Clinical Trial of HTX-011 in Abdominoplasty 39
Jan 04, 2017: Heron Therapeutics Establishes Synergy of Bupivacaine and Meloxicam with HTX-011 for Prevention of Post-Operative Pain in Phase 2 Clinical Studies 40
Sep 08, 2016: Heron Therapeutics Announces Presentations of Results from Phase 2 Clinical Trial of HTX-011 in Hernia Repair at PAINWeek 2016 41
Aug 29, 2016: Heron Therapeutics Announces Poster Presentations of Data from Phase 2 Clinical Program for HTX-011 at PAINWeek 2016 43
Aug 01, 2016: Heron Therapeutics Reports Positive Top-Line Results from Phase 2 Studies of HTX-011 for Management of Post-Operative Pain 44
Appendix 46
Methodology 46
About GlobalData 46
Contact Us 46
Disclaimer 46

List of Tables
Heron Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Heron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Heron Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Heron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Heron Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Heron Therapeutics Inc, Medical Devices Deals, 2011 to YTD 2017 10
Heron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Heron Therapeutics Prices Public Offering of Shares for USD150 Million 12
Heron Therapeutics Raises USD172.6 Million in Public Offering of Shares 14
Heron Therapeutics Raises USD137 Million in Public Offering of Shares 16
Heron Therapeutics Raises USD55.8 Million in Public Offering of Shares 18
Heron Therapeutics Raises USD7 Million in Private Placement of Warrants 20
A.P. Pharma Completes Public Offering Of Shares For US$60 Million 21
A.P. Pharma Completes Private Placement Of Common Stock For US$54 Million 23
A.P. Pharma Completes Private Placement Of Units For US$24 Million 24
A.P. Pharma Completes Intial Closing Of Private Placement Of Convertible Notes For US$1.5 Million 25
Heron Therapeutics Inc, Key Competitors 26
Heron Therapeutics Inc, Key Employees 27
Heron Therapeutics Inc, Other Locations 28

★海外企業調査レポート[Heron Therapeutics Inc (HRTX)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Major Drilling Group International Inc (MDI):企業の財務・戦略的SWOT分析
    Major Drilling Group International Inc (MDI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key stren …
  • Entergy Corporation (ETR)-エネルギー分野:企業M&A・提携分析
    Summary Entergy Corporation (Entergy) is an integrated energy company that generates, transmits, distributes and sells electricity. The company generates electricity from various sources including natural gas, nuclear, coal, hydroelectric and oil based power plants. Entergy also operates a natural g …
  • Aurora Diagnostics LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary Aurora Diagnostics LLC (Aurora Diagnostics) is a healthcare service provider that offers hospital and pathology services. The center’s pathology services include gastrointestinal pathology services, heamato-pathology services, dermatology services, urologic pathology, pathology consultation, …
  • Societe Des Bains De Mer Sa:企業の戦略・SWOT・財務分析
    Societe Des Bains De Mer Sa - Strategy, SWOT and Corporate Finance Report Summary Societe Des Bains De Mer Sa - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Neptune Orient Lines Limited:企業の戦略・SWOT・財務情報
    Neptune Orient Lines Limited - Strategy, SWOT and Corporate Finance Report Summary Neptune Orient Lines Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Hutchinson SA:企業の戦略的SWOT分析
    Hutchinson SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Highland Gold Mining Limited
    Highland Gold Mining Limited - Strategy, SWOT and Corporate Finance Report Summary Highland Gold Mining Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • GVK Power and Infrastructure Ltd (GVKPIL):企業の財務・戦略的SWOT分析
    GVK Power and Infrastructure Ltd (GVKPIL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • Armour Residential REIT, Inc.:企業のM&A・事業提携・投資動向
    Armour Residential REIT, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Armour Residential REIT, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and …
  • Sharp HealthCare:企業の戦略的SWOT分析
    Sharp HealthCare - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Marriott International Inc:企業のM&A・事業提携・投資動向
    Marriott International Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Marriott International Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acqui …
  • Christian Dior SE:企業の戦略・SWOT・財務情報
    Christian Dior SE - Strategy, SWOT and Corporate Finance Report Summary Christian Dior SE - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Virgin Media Inc.:企業の戦略的SWOT分析
    Virgin Media Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Silver Lake Resources Limited:企業の戦略・SWOT・財務情報
    Silver Lake Resources Limited - Strategy, SWOT and Corporate Finance Report Summary Silver Lake Resources Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Kinden Corporation:企業の戦略・SWOT・財務情報
    Kinden Corporation - Strategy, SWOT and Corporate Finance Report Summary Kinden Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Sacgasco Ltd (SGC):企業の財務・戦略的SWOT分析
    Summary Sacgasco Ltd (Sacgasco) formerly Australian Oil Company Ltd, is an energy company that provides conventional oil and gas exploration, development and production across Australia. The company develops and produces clean natural gas in the Sacramento Basin, onshore California. It explores Sacr …
  • Nativis Inc-医療機器分野:企業M&A・提携分析
    Summary Nativis Inc (Nativis) is a clinical stage bio-electronics company. Its portfolio of pipeline candidates which are under development for various therapeutic areas include recurrent glioblastoma, brain metastisis, pain, rheumatoid arthritis, lung cancer and melanoma. The company’s lead product …
  • Leoni AG (LEO):企業の財務・戦略的SWOT分析
    Leoni AG (LEO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • FTI Consulting Inc (FCN):企業の財務・戦略的SWOT分析
    Summary FTI Consulting Inc (FTI) is an independent global consulting service provider. The company offers corporate finance and restructuring, consulting, strategic communications, economic consulting, forensic and litigation, technology and specialty services. It provides it services across various …
  • Alibaba Group Holding Ltd (BABA):企業の財務・戦略的SWOT分析
    Alibaba Group Holding Ltd (BABA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆